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Introduction {#sec1}
============

*LRRK2* (leucine-rich repeat kinase 2) encodes a large (286 kDa), multi-domain cytoplasmic protein, with both guanosine triphosphatase (GTPase) and kinase domains, flanked by several protein-protein interaction domains. Mutations in *LRRK2* account for approximately 4% of familial and 1% of idiopathic cases of the progressive neurodegenerative disorder, Parkinson\'s disease (PD), forming an important genetic risk factor for PD. Most PD-causing mutations cluster within the two enzymatic sites, notably G2019S and R1441C/G (leading to a modest 2- to 3-fold increase in kinase activity and decreased GTPase activity, respectively) ([@bib16]). *LRRK2* variants are also associated with autoimmune disorders ([@bib55]), particularly Crohn\'s disease, and with infectious diseases, notably *Mycobacterium leprae* ([@bib52], [@bib58]). *LRRK2* expression has also been linked with *Mycobacterium tuberculosis* infection ([@bib24], [@bib53]). *LRRK2* is expressed in a variety of cell lineages, including several immune subsets, notably B cells, neutrophils, monocytes, macrophages, and microglia ([@bib1], [@bib13], [@bib18], [@bib23], [@bib30], [@bib37], [@bib38], [@bib49]; reviewed in [@bib32]).

Macrophages populate most tissues of the body, deriving initially from primitive macrophages that migrate in during embryogenesis, and are replenished as necessary during the lifespan by either local proliferation and/or replacement by blood monocyte-derived macrophages, depending on the tissue ([@bib27]). Macrophages perform tissue homeostatic functions and are also a first-line defense against pathogens, armed with a plethora of pattern-recognition and opsonin receptors. They rapidly phagocytose and kill incoming bacteria, fungi, and protoctists, and have strong antiviral defenses. Nonetheless, various pathogens can overcome these defenses to survive and proliferate in macrophages, including *M*. *leprae* and *M*. *tuberculosis*, Interestingly, LRRK2 has recently been shown to be required for survival of *M*. *tuberculosis* in macrophages ([@bib24]).

Microglia are a resident, primitive macrophage-derived population in the central nervous system, performing homoeostatic functions (phagocytosing cell debris, extracellular protein aggregates, and incompetent synapses) to maintain a healthy environment for neurons. However, they can also secrete inflammatory mediators when activated, notably tumor necrosis factor α, and a myriad of cytotoxic factors, especially reactive oxygen species and nitric oxide, which can instigate a feedforward cycle of chronic inflammation and neurodegeneration. Therefore, microglia are not only involved in preventing neurodegenerative disease by phagocytosing potentially harmful materials but also can contribute to disease progression by initiating exaggerated inflammatory responses (reviewed in [@bib56]).

Due to the difficulty in obtaining primary patient material, most studies of LRRK2 have used animal models, *in vitro* biochemical assays, or transformed cell lines, often involving non-physiological exogenous overexpression of LRRK2 in irrelevant lineages. Studies of LRRK2 using transformed myeloid cell lines have progressed this field ([@bib18], [@bib37]), and [@bib11] have reported that LRRK2 recruits and phosphorylates RABs 8 and 10 to chloroquine-induced overload-stressed lysosomes in mouse RAW264.7 cells, leading to release of lysosomal contents. Yet such observations need to be subsequently assessed in a karyotypically normal human cellular system at physiologically relevant expression levels to validate their applicability to normal human physiology and disease. We have previously developed methods for efficient differentiation of human induced pluripotent stem cells (hiPSCs) to macrophages, which exhibit authentic phagocytic properties and cytokine-profiles ([@bib17], [@bib22], [@bib29], [@bib50]). The differentiation pathway is demonstrably independent of c-Myb expression ([@bib5]), indicating that they represent an embryonic/primitive ontogeny and are therefore also suitable as a precursor for differentiation to microglia. We have shown that they can be further differentiated to microglia by co-culture with hiPSC neurons, whereupon they acquire a ramified morphology and associated neuronal surveillance activity ([@bib21]).

In this study, we have used hiPSC macrophages and microglia from patient, control, and gene-edited lines to explore the expression of LRRK2 protein from the endogenous locus and the role of LRRK2 in this lineage. We show that LRRK2 is expressed in hiPSC macrophages and microglia, with expression significantly upregulated by interferon-γ (IFN-γ) and identify the cleavage region of a truncated LRRK2 product found in this lineage. In this system, LRRK2 is not involved in the initial phagocytic uptake of particles but is recruited to maturing phagosomes, and this is exacerbated by inhibition of LRRK2 kinase activity. Importantly, we show that LRRK2 is required for recruitment to phagosomes of RAB8a and RAB10 (members of the membrane trafficking regulator family of RAB GTPases and substrates of LRRK2 kinase activity). This demonstrates that LRRK2 operates at the intersection between phagosome maturation and recycling pathways in the myeloid lineage.

Results {#sec2}
=======

Characterization of LRRK2 Knockout and G2019S Isogenic Control hiPSC Lines and a Major LRRK2 Cleavage Product in Macrophages {#sec2.1}
----------------------------------------------------------------------------------------------------------------------------

The hiPSC lines used in this study are listed in [Table S1](#mmc1){ref-type="supplementary-material"}, with quality control information in [Figure S1](#mmc1){ref-type="supplementary-material"}. Wild-type lines (WT.1 to WT.6) were from six healthy control donors.

*LRRK2* knockout (KO) was generated in a control hiPSC (line WT.1) by a double nickase CRISPR/Cas9 ([@bib40]) strategy, using a pair of guide RNAs (gRNAs) targeting exon 3 of *LRRK2* ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). A patient line containing a heterozygous *LRRK2* mutation G2019S (GS) was successfully repaired to WT (GS-Repair) as shown by sequence analysis ([Figure 1](#fig1){ref-type="fig"}B). Two KO clones (KO.1 and KO.2) displayed out-of-frame homozygous deletion of *LRRK2* ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and showed complete absence of LRRK2 protein when differentiated to macrophages ([Figure 1](#fig1){ref-type="fig"}C). There was no significant difference in the production of macrophage precursors in edited versus parental lines ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).Figure 1Characterization of LRRK2 Knockout and G2019S Isogenic Control hiPSC Lines and a Major LRRK2 Cleavage Product in Macrophages(A) CRISPR/Cas-9-mediated knockout (KO) of *LRRK2* was performed using a double nickase strategy with a pair of guide RNAs (gRNAs, black lines; protospacer adjacent motif \[PAM\], blue lines) targeting exon 3 of *LRRK2*. For CRISPR/Cas-9-mediated repair of *LRRK2* G2019S mutation, the donor template contained silent mutations in the PAM site to maximize gene-editing efficiency and a *Pst*I site for the subsequent screening of edited clones.(B) Sequencing results demonstrate that the G2019S mutation present in one allele (A/G) was successfully corrected to the WT sequence (G/G).(C) Western blot probed with antibody to LRRK2 N241A/34 shows the complete absence of endogenous LRRK2 protein in both KO clones in hiPSC macrophages with or without 72-h IFN-γ (100 ng/mL) activation. The total expression level of LRRK2 protein in the isogenic repaired line is not altered. αTUB, α-tubulin.(D) Western blot showing immunoprecipitated (N241A/34 antibody) endogenous LRRK2 protein from WT- and KO-derived hiPSC macrophages. Silver-stained gel bands corresponding to full-length LRRK2 (fl LRRK2) and the cleaved LRRK2 (cl LRRK2), indicated in red boxes, were cut and analyzed by mass spectrometry.(E) Trypsin-digested peptides were quantified by MaxQuant. Heatmap shows the intensity of identified peptides (ordered from N terminus to C terminus) of fl LRRK2 and cl LRRK2. cl LRRK2 is largely missing N-terminal peptides up to ANK-LRR inter-domain aa 861--983 (chymotrypsin cleavage sites, red; phosphorylation sites, green).

Western blot of hiPSC macrophages using LRRK2 monoclonal antibody N241A/34 (binding site amino acids \[aa\] 1,836--1,845) consistently showed multiple faint bands and a major band (approximately 170 kDa relative to size markers) in addition to full-length LRRK2 (286 kDa). This was particularly evident upon IFN-γ stimulation. The staining pattern was confirmed to be *LRRK2* specific by its absence in LRRK2 KO hiPSC macrophages ([Figure 1](#fig1){ref-type="fig"}C). Since LRRK2 transcripts that would correspond to this product have not been reported, we reasoned that this is likely a proteolytically cleaved product. It is not a result of technical post-lysis proteolysis, as spiking recombinant full-length LRRK2 into *LRRK2*-KO macrophage lysate did not lead to its proteolytic degradation under our standard lysis conditions ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Addition of protease inhibitors to live macrophages reduced the proportion of the truncated versus full-length protein, implying that it is a natural cleavage generated within intact macrophages ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Immunoprecipitation using the N-terminal antibody revealed that the cleaved product can heterodimerize with full-length LRRK2 ([Figures S2](#mmc1){ref-type="supplementary-material"}F and S2G). To identify the cleavage site, we isolated endogenous LRRK2 protein from hiPSC macrophages by immunoprecipitation with N241A/34 antibody, ran it on a denaturing gel, and analyzed the cleaved product by mass spectrometry ([Figure 1](#fig1){ref-type="fig"}D). MaxQuant analysis of trypsin-digested peptide fragments revealed that cleavage occurs within the ANK-LRR interdomain region (aa 861--983), generating a C-terminal predicted product of ∼170--187 kDa ([Figure 1](#fig1){ref-type="fig"}E). Western blot of hiPSC macrophage whole-cell lysate using an antibody against LRRK2 pSer935, did not co-localize with the C-terminal cleavage product band but did co-localize with a ∼110-kDa band detected by the N-terminal antibody, and treatment of the cells with LRRK2 kinase inhibitor GNE-7915 (GNE) reduced the intensity of the pSer935 band ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Together, these results indicate that S935 can be present on the N-terminal cleavage product, predicting the major cleavage site to be downstream of S935.

IFN-γ Increases LRRK2 Protein Expression in hiPSC Macrophages and Microglia {#sec2.2}
---------------------------------------------------------------------------

IFN-γ has been shown to upregulate LRRK2 protein expression in myeloid cells ([@bib18]). Similarly, in hiPSC macrophages, LRRK2 protein expression increased significantly (up to 10-fold) upon IFN-γ treatment ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Phosphorylation of LRRK2 at S935 was observed, significantly decreasing in the presence of LRRK2 kinase inhibitor GNE, in accordance with the published literature ([@bib25]) ([Figure 2](#fig2){ref-type="fig"}B). hiPSC macrophages with the heterozygous G2019S mutation showed the same pattern, with no significant difference in either the basal phosphorylation level at S935 or the degree of dephosphorylation upon treatment with LRRK2 kinase inhibitors compared with its isogenic pair ([Figure S3](#mmc1){ref-type="supplementary-material"}B), likely because G2019S only produces a modest 2-fold increase in kinase activity.Figure 2IFN-γ Increases LRRK2 Protein Expression in hiPSC Macrophages and Microglia(A) hiPSC macrophages were treated with IFN-γ (100 ng/mL) for 16, 48, and 72 h and cell lysates were analyzed by western blot. Bar graph shows fold change of the total endogenous LRRK2 protein over loading control (α-tubulin \[αTUB\]).(B) hiPSC macrophages were treated with LRRK2 kinase inhibitor GNE-7915 (GNE; 1 μM) for 30, 60, and 120 min after 72-h treatment with IFN-γ. Bar graph shows fold change in pS935-LRRK2 signal over total LRRK2 relative to DMSO control. All data points in (A) and (B) represent mean ± SEM of at least three independent experiments.(C) Microglia differentiated from either WT or KO hiPSC were co-cultured with cortical neurons differentiated from WT hiPSC. Cells were treated with IFN-γ (100 ng/mL) for 48 h and were stained with antibodies against neuronal marker (MAP2), microglial marker (IBA1), and LRRK2 (N241A/34). (C) and (D) scale bars represent 100 μm.(D) hiPSC microglia co-cultured in hiPSC neurons were treated with IFN-γ (100 ng/mL) for 0, 16, 48, and 72 h. z-stacked confocal images were acquired and the number of hiPSC microglia (IBA1-positive cells) expressing LRRK2 was quantified using Columbus software (PerkinElmer). Bar graph shows percentage of LRRK2-expressing hiPSC microglia as mean ± SEM of three independent experiments. (A), (B) and (D) statistical significance was tested using one-way ANOVA, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, not significant, ns: p \> 0.05. Generation of *LRRK2* modified hiPSC lines.

We next examined LRRK2 expression in hiPSC microglia, co-cultured with hiPSC cortical neurons. LRRK2 protein was clearly expressed in hiPSC microglia while its expression level was not detectable in hiPSC cortical neurons ([Figure 2](#fig2){ref-type="fig"}C). The specificity of LRRK2 staining in microglia was confirmed by co-culturing microglia differentiated from LRRK2 KO hiPSCs with cortical neurons differentiated from LRRK2 WT hiPSCs ([Figure 2](#fig2){ref-type="fig"}C). To test whether IFN-γ upregulates LRRK2 protein in hiPSC microglia or neurons, we treated hiPSC microglia/cortical neuron co-cultures with IFN-γ for 16 h, 48 h, or 72 h. IFN-γ treatment significantly upregulated the percentage of LRRK2 expressing hiPSC microglia to 86%, its expression level plateauing by 48 h post IFN-γ treatment ([Figure 2](#fig2){ref-type="fig"}D).

Together, these results demonstrate the validity of the hiPSC macrophage and microglia models for investigating endogenous LRRK2 function.

LRRK2 Is Not Involved in the Initial Phagocytic Uptake of Bioparticles but Is Recruited to Maturing Phagosomes {#sec2.3}
--------------------------------------------------------------------------------------------------------------

We next investigated whether LRRK2 is involved in phagocytosis using hiPSC macrophages. hiPSC macrophages readily phagocytose a wide variety of "meals," including killed yeast bioparticles ("zymosan"), a process ablated by inhibiting actin polymerization with cytochalasin D. Complete absence of LRRK2 in hiPSC macrophages did not alter their ability to take up fluorescent zymosan, with or without IFN-γ induction ([Figures 3](#fig3){ref-type="fig"}A and 3B). Similarly, zymosan uptake by G2019S patient-derived hiPSC macrophages was not significantly different from that of its isogenic pair ([Figure 3](#fig3){ref-type="fig"}C). Lastly, pharmacological inhibition of LRRK2 kinase activity with two structurally distinct LRRK2 kinase inhibitors, GSK2578215A (GSK) or GNE, had no significant effect on zymosan uptake ([Figure 3](#fig3){ref-type="fig"}D). Acidification of the phagosomes, as assessed by uptake of pH-sensitive fluorescent (pHrodo) zymosan particles, was also not significantly altered by manipulating LRRK2 in hiPSC macrophages ([Figure S4](#mmc1){ref-type="supplementary-material"}).Figure 3LRRK2 Is Not Involved in the Initial Phagocytic Uptake of Bioparticles(A) Outline of the experimental design.(B and C) hiPSC macrophages differentiated from the two isogenic pairs (B, WT and KO; C, GS and GS-Repair) were treated with IFN-γ for 3 days, then pre-treated with either DMSO or 10 μM cytochalasin D (CytD, to inhibit actin polymerization as a negative control) for 1 h before incubation with Alexa Fluor 488-conjugated zymosan bioparticles for 30 min. Bar graphs show the percentage of zymosan^+^ cells as mean ± SEM.(D) hiPSC macrophages from three healthy controls (WT.1, WT.2, WT.3) were pre-treated with LRRK2 kinase inhibitors (GNE or GSK; 1 μM) prior to the addition of zymosan bioparticles. Each dot represents data from each independent experiment. (B-D) two-way ANOVA with Dunnett multiple comparisons was used for statistical analysis, ^∗∗∗∗^p \< 0.0001, not significant, ns: p \> 0.05.

While no functional difference in initial phagocytic uptake was observed across LRRK2 lines, confocal imaging clearly demonstrated the presence of LRRK2 on a subset of zymosan-containing phagosomes (in IFN-γ-treated cells to enable visualization of LRRK2) ([Figure 4](#fig4){ref-type="fig"}A). This was also observable with *Escherichia coli* bioparticles, with and without opsonization, and *Salmonella typhimurium* ([Figure 4](#fig4){ref-type="fig"}A). LRRK2 was not observed on phagosomes containing αsyn fibrils, even when opsonized ([Figure S5](#mmc1){ref-type="supplementary-material"}), indicating that LRRK2 recruitment is context dependent. The number of LRRK2-positive (LRRK2^+^) zymosan-containing phagosomes was time dependent, peaking at 1--2 h after addition of the meal to cells (mean 14.7%, range 6.8%--25.2% at 2 h), so 2-h zymosan incubation was used for all subsequent experiments ([Figure 4](#fig4){ref-type="fig"}B). LRRK2^+^ phagosomes were found to also be positive for the late phagosomal markers lysosome-associated protein LAMP-1 and RAB9, with significantly more LRRK2^+^LAMP-1^+^ or LRRK2^+^RAB9^+^ phagosomes than LRRK2^+^RAB5^+^ phagosomes (an early phagosome marker) ([Figure 4](#fig4){ref-type="fig"}C). Together, these data show that LRRK2 is recruited during later stages of phagosome maturation in hiPSC macrophages, around the time when lysosomes are recruited to phagosomes.Figure 4LRRK2 Is Recruited to Maturing Phagosomes(A) Confocal images of LRRK2 WT and LRRK2 KO hiPSC macrophages fed with zymosan, immunoglobulin G (IgG)-opsonized zymosan (Op-Zymosan), *E*. *coli*, IgG-opsonized *E*. *coli* (Op-*E*. *coli*), GFP-expressing *S*. *typhimurium* (all Alexa Fluor 488 conjugated). Phagocytosis proceeded for 2 h before cells were fixed and stained with antibody against LRRK2. All scale bars represent 10 μm.(B) Quantification of LRRK2^+^ phagosomes over time. Each data point represents the percentage of total phagosomes that were LRRK2^+^ (by automated image analysis), mean of 20 random fields. Note that low absolute numbers of phagosomes earlier than 30 min precluded accurate LRRK2 quantification.(C) hiPSC macrophages fed with zymosan bioparticles were stained with antibodies against LRRK2 and markers associated with maturing phagosomes, LAMP1 and RAB9. Internalized zymosan bioparticles are indicated by an asterisk to better visualize decoration of phagosome membrane by LRRK2 and marker staining. Bar graph shows fold change in the number of LRRK2^+^ phagosomes displaying late phagosomal markers versus early phagosome marker (RAB5). Two-way ANOVA with Dunnett\'s multiple comparisons test was used for statistical analysis,^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

RAB8a and RAB10 Are Recruited to Phagosomes, and This Is LRRK2 Dependent {#sec2.4}
------------------------------------------------------------------------

RAB GTPases regulate various fission and fusion events during phagocytosis, and in LRRK2-overexpression systems and non-human systems LRRK2 has been shown to associate physically with subsets of this family of proteins ([@bib9], [@bib19], [@bib48], [@bib54], [@bib57]). Importantly, several RABs, particularly RAB8a and RAB10, have been identified as physiological substrates of LRRK2, able to be phosphorylated by LRRK2 (on Thr72/73, respectively) ([@bib13], [@bib48]). We therefore investigated whether these RAB GTPases are involved during LRRK2 recruitment to phagosomes. RAB8a and RAB10 could be observed coating the same phagosomes as LRRK2, while RAB7 had no significant association with LRRK2^+^ phagosomes ([Figures 5](#fig5){ref-type="fig"}A and 5B). 14-3-3 proteins, which associate with pS935-LRRK2 ([@bib10]), did not appear closely co-localized with LRRK2 but could be observed just peripheral to LRRK2-coated clusters of phagosomes (not quantified). Importantly, the number of RAB8^+^ and RAB10^+^ phagosomes was significantly reduced (to background levels) in LRRK2 KO hiPSC macrophages ([Figures 5](#fig5){ref-type="fig"}A and 5C), and the number of phosphoT73 RAB10^+^ phagosomes was also significantly reduced ([Figures 5](#fig5){ref-type="fig"}D and 5E), demonstrating that the presence of LRRK2 is necessary for recruitment of RAB8a and RAB10 to phagosomes.Figure 5RAB8 and RAB10 Are Recruited to Phagosomes, and This Is LRRK2 Dependent(A) Confocal images of LRRK2 WT and LRRK2 KO hiPSC macrophages fed with zymosan Alexa Fluor 488 for 2 h, then fixed and stained for LRRK2 (Alexa Fluor 647, red) and RABs (RAB10 D36C4) or pan-14-3-3 protein (Alexa Fluor 546, yellow). Scale bars represent 10 μm.(B) Quantification of number of LRRK2^+^ phagosomes that are also RAB^+^. Data from four WT hiPSC macrophage lines (WT.1, WT.2, WT.4, WT.6); each data point represents the mean of 20 fields per independent replicate. Control, secondary antibody only.(C) Quantification of RAB^+^ phagosomes; each data point represents the mean of 20 fields per independent replicate.(D) Images as in (A) but stained for phosphoT73 RAB10 (Ab230261).(E) Quantification of (D), each data point represents the mean of 20 fields per independent replicate, overall mean ± SD.One-way ANOVA with Tukey\'s multiple comparison was performed for all statistical analyses, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, not significant, ns: p \> 0.05.

LRRK2 Kinase Inhibitors Increase LRRK2 Density at Phagosomes but Inhibit RAB8a and RAB10 Recruitment {#sec2.5}
----------------------------------------------------------------------------------------------------

In LRRK2-overexpressing HEK 293T cells, it has been reported that LRRK2 kinase inhibitors affect localization of LRRK2 within the cell, from diffused cytosolic distribution to more discrete cytosolic pools ([@bib10]). Therefore, we investigated whether the application of LRRK2 kinase inhibitors would affect LRRK2 recruitment to phagosomes during phagocytosis. Pre-treating hiPSC macrophages with LRRK2 kinase inhibitors did not change the total number of LRRK2^+^ phagosomes. However, we noticed that significantly more (4-fold) of these LRRK2^+^ phagosomes displayed enhanced LRRK2 signal (referred to as "supercoated" LRRK2 phagosomes, LRRK2^++^, [Figures 6](#fig6){ref-type="fig"}A--6C). This was also observable with the LRRK2 G2019S patient line and its isogenic control ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). There was no significant difference between the isogenic pair of lines, suggesting that monoallelic G2019S LRRK2 kinase enhancement is not potent enough to give a detectable difference in "supercoating" compared with strong drug-induced kinase inhibition.Figure 6LRRK2 Kinase Inhibitors Increase LRRK2 Density at Phagosomes but Inhibit RAB8 and RAB10 Recruitment(A) hiPSC macrophages were pre-treated with GSK (1 μM) or GNE (1 μM) for 2 h or 16 h before Alexa 488 zymosan bioparticles were added. Phagocytosis proceeded for 2 h, then cells were fixed and stained with antibody against LRRK2.(B) Confocal images show examples of LRRK2^+^ phagosomes (single-headed arrows) and LRRK2^++^ ("supercoated") phagosomes (double-headed arrows).(C) Quantification of (B). Each dot shows data (mean) collected from at least 300 cells based on images acquired from at least five randomized fields. Two-way ANOVA with Fisher\'s least significant difference test was used for the statistical analysis.(D) Confocal images show lack of recruitment of RAB10 (Ab181367) to LRRK2^++^ phagosome in the presence of LRRK2-kinase inhibitor GNE (16 h), whereas DMSO control shows co-localization of the two proteins at phagosomes (left-hand panel); right-hand panel shows the same but for phosphoT73 RAB10 (Ab241060).(E) Quantification of (D). Data from three independent hiPSC-derived macrophage lines; each data point represents the mean of 20 fields per independent replicate, with overall mean ± SD, one-tailed unpaired t test with Welch\'s correction. (C) and (E) ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, not significant, ns: p \> 0.05. (B) and (D) scale bars represent 10 μm.

Although LRRK2 kinase inhibition led to an increase in LRRK2 presence at phagosomes, RAB8a and RAB10 co-localization at LRRK2^+^ phagosomes was reduced ([Figures 6](#fig6){ref-type="fig"}D, 6E, [S6](#mmc1){ref-type="supplementary-material"}C, and S6D). This observation was also replicated in the G2019S isogenic pair ([Figure S6](#mmc1){ref-type="supplementary-material"}E). Note that while kinase inhibition significantly reduced RAB8a andRAB10 recruitment, there was no significant difference between the G2019S line and its isogenic corrected line, implying again that this monoallelic mutation is subtle in relation to the effects of potent chemical inhibitors. Importantly, LRRK2 kinase inhibition also significantly reduced detection of phosphoRAB10 at phagosomes ([Figures 6](#fig6){ref-type="fig"}D and 6E). Together, these results show that although kinase inhibition causes LRRK2 to accumulate on phagosomes, without kinase activity LRRK2 cannot recruit RAB8a or RAB10.

Discussion {#sec3}
==========

Here, we have characterized a platform for understanding LRRK2 function using hiPSC-derived macrophages and microglia, including gene-edited lines, which has enabled us to interrogate the involvement of LRRK2 in phagocytic processes in authentic, professional phagocytes.

While numerous studies have used hiPSC-derived neurons and astrocytes to study LRRK2 function (reviewed in [@bib4]), the advantages of iPSC technology have barely begun to be applied to studying its function in the myeloid lineage. Our hiPSC macrophages have been used in one previous study as a validation of observations in mouse that *M*. *tuberculosis* survival inside macrophages requires LRRK2 ([@bib24]). To our knowledge, only one other group has previously looked at LRRK2 in hiPSC-derived myeloid cells, describing an impact of the G2019S mutation on differentiation capacity ([@bib46]); however, we did not find this in our system over multiple differentiations with our G2019S isogenic pair or our LRRK2 KO isogenic pair.

We show that endogenous LRRK2 in hiPSC macrophages and microglia is strongly induced by immune signals, particularly IFN-γ, as reported in other systems ([@bib18], [@bib32]) This upregulation reveals additional bands by western blot, notably a prominent band running at ∼170--187 kDa (predicted from proteomic analysis), possibly equivalent to the ∼160-kDa truncated product reported by others in mouse kidney proximal tubule cells (also detectable in lung and spleen but not brain) ([@bib26]). Since it does not include S935, it appears not to correspond exactly to the ∼200-kDa product reported in neutrophils and peripheral blood mononuclear cells ([@bib13]). We have identified the LRRK2 cleavage region in hiPSC macrophages to be within the ANK-LRR interdomain region, likely more susceptible to cleavage, particularly if 14-3-3 proteins are not bound to the nearby S910/S935 phosphorylation sites. Structural modeling predicts that LRRK2 dimers have C-terminal (kinase and WD40) domains folded backward, in contact with N-terminal domains, suggesting that N-terminal domains may modulate enzymatic activity ([@bib20]). While this cleavage product could be merely the first stage of LRRK2 degradation, it could also, by lacking the N-terminal Armadillo/Ankyrin domains, affect LRRK2 cellular localization, kinase activity, and/or interaction with other proteins.

In our assays, LRRK2 did not impact on the initial uptake of phagocytic particles. Previous studies have yielded conflicting results regarding LRRK2 and phagocytic uptake. Small interfering RNA-mediated knockdown of LRRK2 has been variously reported to reduce phagocytic uptake in mouse microglial transformed BV-2 cells ([@bib37]) and, conversely, to have no effect in mouse macrophage transformed RAW264.7 cells and BV-2 cells ([@bib44]), nor in primary mouse *LRRK2* KO microglia versus WT ([@bib24], [@bib36]). A recent study across multiple systems (fly, mouse, and Parkinson\'s patients) has implicated LRRK2 in phagocytic uptake of beads or *E*. *coli* through LRRK2 phosphorylating the actin-remodeling complex component, WAVE2 ([@bib31]). It is not clear why our results diverge from this study, as hiPSC macrophages express levels of WAVE2 similar to those of primary human monocytes and microglia ([@bib21]), but it may reflect technical differences (e.g., that study used serum-containing medium, which can lead to engagement of different receptor subsets; and *ex vivo* primary cells may reflect background donor physiological status) that could affect the engagement of the actin-remodeling complex and the relative impact of LRRK2 in the process ([@bib43]).

Our observations that in hiPSC macrophages LRRK2 is recruited to late phagosomes containing zymosan, *E*. *coli*, or *S*. *typhimurium*, extends the observation made by [@bib18], who observed recruitment of LRRK2 to *S*. *typhimurium*-containing phagosomes in RAW264.7 cells. Zymosan engages Toll-like receptor 2 (TLR2) and dectin-1 receptors, *E*. *coli* engages TLR4, and *S*. *typhimurium* engages TLR2/TLR4. We did not observe LRRK2 recruitment to α-synuclein (αsyn) fibrils under these experimental conditions. Oligomeric αsyn engages TLR1/2, and monomeric αsyn engages TLR4 ([@bib14], [@bib30]), but exactly which receptors αsyn fibrils engage is currently unclear. The relationship between LRRK2 and aggregated αsyn is not, therefore, as clear-cut as between LRRK2 and bacterial and fungal pathogens in this phagocytic context.

In our system, LRRK2 co-localizes with late phagocytic markers RAB9 and LAMP1 rather than with the early phagocytic marker RAB5, and also co-localizes with RAB8a and RAB10 but not with RAB7. RAB9 facilitates the recycling of mannose 6-phosphate receptors (M6PRs) between the phagosomes and the *trans*-Golgi network (TGN). M6PRs are important in delivering newly synthesized lysosomal enzymes from the TGN to phagosomes ([@bib41]). LAMP-1, while found abundantly on lysosomes ([@bib12]), is recruited to phagosomes prior to RAB7 recruitment, which is required for the formation of phagolysosomes ([@bib28]). Therefore, it is conceivable that LRRK2 is recruited prior to recruitment of RAB7. RAB8a is involved in vesicle transport and membrane recycling to the cell surface ([@bib2]), autophagy (with the amyotrophic lateral sclerosis-related gene, C9orf72, implicated as a RAB8 GEF) ([@bib7]), and has previously been linked to LRRK2 in, variously, endolysosomal trafficking ([@bib42]), centrosome function ([@bib35]), and ciliogenesis ([@bib47]). RAB10 has been associated with TLR4 recycling to the surface from endosomes/Golgi ([@bib51]) and has also been implicated in LRRK2-mediated ciliogenesis ([@bib47]). Therefore, these RABs could be recruited by LRRK2 to maturing phagosomes in our system to participate in recycling/rerouting of phagocytosed membrane, receptors, and contents. [@bib24] implicate LRRK2 in retarding *M*. *tuberculosis* phagosome maturation. Combined with our findings here, it is conceivable that LRRK2 provides links to alternative fates for phagosomal components and contents other than a direct route to total proteolysis.

[@bib47] identified RABs as bona fide substrates of LRRK2, with RAB3A/B/C/D, RAB8A/B, RAB10, RAB12, RAB35, and RAB43 as the subset of RABs phosphorylated by LRRK2 in cells, and phosphorylation of RAB10 has been exploited as a readout of LRRK2 kinase activity in human neutrophils ([@bib13]). We have demonstrated that RAB10, which co-localizes with LRRK2 at phagosomes and whose recruitment is dependent on LRRK2 presence and kinase activity, is phosphorylated by LRRK2 at this location. We have, therefore, extended the observations of [@bib11] in chloroquine-stressed mouse myeloid lines (briefly also noting LRRK2 recruitment to zymosan phagosomes) to show LRRK2-dependent RAB8a and RAB10 recruitment to phagosomes in authentic human macrophages, using phagocytosis of bioparticles as a physiologically relevant system rather than chemically induced lysosomal stress, and we have observed LRRK2 "supercoating" of phagosomes upon LRRK2 kinase inhibitor treatment. Accumulation of kinase-inhibited LRRK2 suggests that LRRK2 does not need kinase activity to be recruited to phagosomes but needs to phosphorylate a substrate in order to leave the phagosome. Alternatively, it is possible that LRRK2 inhibitor-induced loss of S935 phosphorylation and 14-3-3 binding dictate supercoating rather than kinase activity per se, and might also explain the similar supercoating seen with the G2019S isogenic pair. iPSC macrophages harboring R1441 mutations (with increased kinase activity but reduced S935 phosphorylation) or edited to express S935A LRRK2 (with normal kinase activity) or kinase dead LRRK2 (still phosphorylated on S935) would resolve this open question.

Most papers studying LRRK2 function rely on biochemical approaches, western blot, and tagged or overexpressed constructs, which may not localize properly, due to tagging and/or overexpression leading to incorrect stoichiometry with other proteins. By optimizing staining for visualizing LRRK2 in hiPSC macrophages by confocal microscopy, we have been able to interrogate the translocation of endogenous, untagged LRRK2 within relevant human cells, revealing the point during phagosome maturation that LRRK2 recruits RAB8a and RAB10 and pointing to a possible role for LRRK2 in rerouting and recycling phagocytosed membrane, receptors, and contents.

Experimental Procedures {#sec4}
=======================

Generation of *LRRK2* Modified hiPSC Lines {#sec4.1}
------------------------------------------

The iPSC lines used in this paper were derived from dermal fibroblasts using non-integrating Sendai reprogramming vectors (Cytotune, Life Technologies), from donors recruited through StemBANCC ([@bib39])/Oxford Parkinson\'s Disease Center: participants were recruited to this study having given signed informed consent, which included derivation of hiPSC lines from skin biopsies (Ethics Committee: National Health Service, Health Research Authority, NRES Committee South Central, Berkshire, UK, who specifically approved this part of the study \[REC 10/H0505/71\]). They are deposited in the European Bank for Induced Pluripotent Stem Cells, EBiSC, <https://cells.ebisc.org/>and listed in hPSCreg, <https://hpscreg.eu/>. See [Table S1](#mmc1){ref-type="supplementary-material"} for details of lines ([@bib6], [@bib8], [@bib15], [@bib22]) and [Figure S1](#mmc1){ref-type="supplementary-material"} for relevant characterization data. Whole-exome sequencing revealed no deleterious LRRK2 mutations in any of the donor fibroblasts other than G2019S in the patient-derived line. iPSCs were maintained in mTeSR1 (STEMCELL Technologies) or E8 (Life Technologies), on hESC-qualified Matrigel-coated (Becton-Dickinson) or Geltrex-coated (Life Technologies) plates, and passaged as clumps with 0.5 mM EDTA in PBS ([@bib3]). Large-scale SNP-QCed frozen batches were used for experiments to ensure consistency.

Differentiation of Macrophages and Microglia from hiPSCs {#sec4.2}
--------------------------------------------------------

Macrophages and microglia were differentiated using previously published protocols ([@bib21], [@bib50]). See [Table S3](#mmc1){ref-type="supplementary-material"} for media compositions. In brief, embryoid bodies were generated in mTeSR medium with bone morphogenetic protein 4, vascular endothelial growth factor, and stem cell factor, then differentiated along a primitive myeloid pathway in T175 flasks in X-VIVO 15 medium with macrophage colony-stimulating factor (M-CSF) and interleukin-3 (IL-3). After about 3 weeks onward, macrophage precursors emerging into the supernatant were harvested, passed through a 40-μm cell strainer, centrifuged for 5 min at 400 × *g*, and further differentiated for 1 week into macrophages in X-VIVO 15 containing 100 ng/mL M-CSF, with a 50% medium change at day 4.

Dual SMAD inhibition was used to differentiate cortical neurons from hiPSCs, based on [@bib45]. Day-43 cortical neurons were then co-cultured with macrophage precursors in microglia differentiation medium containing IL-34 granulocyte M-CSF and underwent 14 days of differentiation in co-culture as described by [@bib21].

Quantification of LRRK2-Positive Phagosomes {#sec4.3}
-------------------------------------------

For each experiment, 50,000 macrophage precursors were seeded and differentiated for 1 week in separate wells of an Ibidi 96-well μ-plate (Ibidi \#89626). hiPSC macrophages were treated with IFN-γ (100 ng/mL) for 72 h to increase expression of endogenous LRRK2 prior to the addition of the phagocytic materials: Alexa Fluor 488-conjugated zymosan (Life Technologies \#Z23373), Alexa Fluor 488-conjugated *Escherichia coli* (Life Technologies \#E13231), and GFP-expressing *S. typhimurium* (Tocris, NCTC 12023, MM11-25). Oregon Green 488-conjugated αsyn fibrils (gift from Dr Kelvin Luk, University of Pennsylvania) were prepared with endotoxin depletion according to the published methods, tested for endotoxin levels, and used at a final dilution of ≤0.01 EU/mL endotoxin (a level considered negligible) ([@bib33], [@bib34]).

After 2 h, cells were washed, fixed, and stained as described above. Five to 20 z-stacked confocal images per well were acquired from randomized fields using an Opera Phenix High Content Screening System (PerkinElmer) with a 63× objective. Quantification of phagosomes was carried out by the Columbus Image Data Storage and Analysis System (CambridgeSoft). Detailed methods used for the analysis are described in [Supplemental Information](#app1){ref-type="fn"}.

Flow-Cytometry Phagocytosis Assays {#sec4.4}
----------------------------------

Uptake of bioparticles was quantitatively assessed by adding Alexa Fluor 488-conjugated zymosan bioparticles (Life Technologies \#Z23373) to hiPSC macrophages (two bioparticles per cell) for 30 min at 37°C, followed by wash steps with PBS and trypan blue (250 μg/mL in PBS) to quench non-internalized bioparticles. Cells were detached by TrypLE and gentle manual scraping, centrifuged at 400 × *g* for 5 min, and fixed with 4% formaldehyde in PBS. Internalized zymosan particles were quantified using a Becton-Dickinson FACSCalibur flow cytometer (BD Biosciences) and analyzed using FlowJo software.

Statistics {#sec4.5}
----------

Statistical analysis was carried out with GraphPad Prism. All data are represented as mean ± SEM of at least three independent experiments carried out by using cells collected from at least three independent differentiation batches unless stated otherwise. When comparing the means from multiple groups against one control group, one-way analysis of variance (ANOVA) with Dunnett\'s post hoc comparison or, for data not displaying normal distribution, non-parametrical Kruskal-Wallis with Dunnett\'s post hoc comparison were used, unless stated otherwise. Statistical significance is presented in the figures as ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001, and not significant (ns; p \> 0.05).
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